The short answer
If you take phenobarbital long term, ask whether vitamin D assessment or supplementation belongs in your bone-health plan. The need and dose depend on your risks and results.
What this answer covers
Vitamin D2/D3 nutrition during long-term oral treatment; no inference that every user is deficient.
- Supplement or preparation
- Vitamin D
- Medication ingredient
- phenobarbital
Assess your personal bone risks
Long-term treatment is the relevant setting. Limited sunlight, poor calcium intake and prolonged immobility are among the factors highlighted in safety guidance. Ask what assessment is appropriate for you.
What supplementation studies can tell us
An older controlled trial included people taking phenobarbital, primidone or phenytoin and found improved bone mineral content with vitamin D2. The mixed groups do not define the benefit or dose for one particular medicine.
Use an individualized plan
Bring every vitamin product so the clinician can check your total intake. These findings do not establish that everyone needs high-dose vitamin D or that a few hours between doses prevents bone effects.
Keep the prescribed medicine steady
Do not stop phenobarbital abruptly or adjust its dose to compensate for a supplement. Sudden withdrawal can provoke serious seizures. Tell the prescriber about new or worsening symptoms and all supplement changes.
Evidence and practical considerations
Timing & monitoring
Exact named-drug safety guidance supports vitamin D consideration for at-risk long-term users, with trial support limited by mixed medication groups and surrogate outcomes.
- Exact scope
- Vitamin D2/D3 nutrition during long-term oral treatment; no inference that every user is deficient. with Exact oral phenobarbital; parent and metabolites distinguished; no other drug/route assumed equivalent.
- Medication form and route
- oral supplement unless pregnancy section explicitly distinguishes neonatal injection
- Timing or duration
- Preparation, dose and duration determine applicability; chronic nutrition evidence is not a single-dose interaction.
What remains uncertain
- No universally optimal dose, proof of fracture protection from vitamin D alone, or supplement spacing interval. D2 trial outcomes are not an exact quantitative D3 prediction.
Factors that may matter: exact supplement identity; dose; other medicines; clinical indication; baseline nutrition; pregnancy where relevant.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral phenobarbital.
Causes CNS depression and can impair driving; other CNS depressants can add to these effects. Adult plasma half-life is prolonged. Abrupt withdrawal after dependence can cause seizures and other serious symptoms. Long-term treatment warrants periodic clinical and laboratory assessment.
How this applies: Exact RxCUI 8134 IN and UNII YQE403BP4D, oral plain ingredient; no automatic sodium-injection or other barbiturate transfer.
Does not name the requested botanicals or establish supplement-specific interaction rates or spacing. Current DailyMed listing is unapproved drug other, not evidence of FDA approval.
Source 2: official medication safety guidance
gov.uk · Source check Sep 10, 2026
Population: Patients receiving long-term antiseizure treatment, particularly those with nutritional or other bone risks.
Both named drugs are associated with osteomalacia. Vitamin D supplementation should be considered for at-risk long-term users; poor calcium intake, limited sunlight and immobility are risk factors.
How this applies: Exact named medications support conditional assessment of long-term bone and nutritional risk.
Guidance does not mean every user has a deficiency, requires the same dose, or benefits from a spacing interval. Older safety review, not a new randomized trial.
Source 3: original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 226 epilepsy outpatients treated with one or two drugs including phenobarbitone, primidone and phenytoin.
Average forearm bone mineral content increased during vitamin D2 treatment and remained unchanged in placebo/control groups.
How this applies: Apply only to the named drugs and study exposures; no unmeasured parent/metabolite or preparation equivalence.
Mixed medication population and surrogate outcome; abstract does not isolate exact-drug benefit, fracture prevention, D3 equivalence or an optimal current dose.
Source 4: original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 80 male veterans with long-term epilepsy treatment; 53 completed two years.
Bone density improved in many participants; added risedronate improved lumbar-spine density more and fractures occurred only in placebo group.
How this applies: Apply only to the named drugs and study exposures; no unmeasured parent/metabolite or preparation equivalence.
No unsupplemented control and no isolated phenobarbital effect. Cannot attribute all improvement to supplements or use it as a primidone-specific trial.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Exact current available claims reviewed against captured originals; no clinical review asserted. | |
| Research summary published |
Article revision: f016dec414ac8757
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.